🟢 Spero Therapeutics is trading 6.72% up in pre-market after Q2 earnings beat estimates

Spero Therapeutics is trading at $1.27 (+6.72%) in pre-market after Q2 2026 earnings beat estimates.

• Q2 2026 adjusted loss was $0.16 per share, beating the $0.17 estimate.
• Management highlighted FDA approval of Utebzi, $105 million in royalty financing, and cash runway into the second half of 2029.
• Revenue was zero and net loss totaled $9.6 million, while the financing and immunology pivot strengthened its outlook.